| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| AMGN | Amgen Inc. | $200.81 | $129.98B | N/A |
5 Biotech Stocks Hit Hard by Hillary Clinton's Tweet
http://www.zacks.com/stock/news/190981/5-biotech-stocks-hit-hard-by-hillary-clintons-tweet?cid=CS-ZC-FT-190981
Sep 22, 2015 - The biotech sector was hit hard by Hillary Clinton's tweet about skyrocketing drug prices and her intention to come up with a plan.
0
Stock Market News for September 22, 2015
http://www.zacks.com/stock/news/190892/stock-market-news-for-september-22-2015?cid=CS-ZC-FT-190892
Sep 22, 2015 - Dennis Lockhart’s willingness to raise rates this year along with gains in financial and technology shares helped benchmarks end in the green on Monday
0
Amgen's Kyprolis Label Expansion Under Priority Review
http://www.zacks.com/stock/news/190816/amgens-kyprolis-label-expansion-under-priority-review?cid=CS-ZC-FT-190816
Sep 21, 2015 - Amgen (AMGN) gets priority review for Kyprolis label expansion; response from the FDA should be out by Jan 22, 2016.
0
Yellen Doesn't Raise Rates: 4 Biotech Stocks to Buy
http://www.zacks.com/stock/news/190599/yellen-doesnt-raise-rates-4-biotech-stocks-to-buy?cid=CS-ZC-FT-190599
Sep 18, 2015 - Continued zero interest-rate policy of keeping the borrowing costs low has sparked concerns in investors about potential asset bubbles and inflation movements.
0
Amgen to Acquire Dezima Pharma, Strikes Deal with Xencor
http://www.zacks.com/stock/news/190477/amgen-to-acquire-dezima-pharma-strikes-deal-with-xencor?cid=CS-ZC-FT-190477
Sep 17, 2015 - Amgen (AMGN), to buy cardiovascular focused company, Dezima Pharma, strikes a deal with Xencor targeting areas of cancer immunotherapy and inflammation.
0
Amgen Seeks FDA Approval for Repatha's New Dosing Option
http://www.zacks.com/stock/news/189982/amgen-seeks-fda-approval-for-repathas-new-dosing-option?cid=CS-ZC-FT-189982
Sep 14, 2015 - Amgen (AMGN) is looking to gain FDA approval for a 420 mg monthly dose of Repatha to be given as a single injection.
0
Will Kite (KITE) Get Orphan Status Again in EU for KTE-C19?
http://www.zacks.com/stock/news/189966/will-kite-kite-get-orphan-status-again-in-eu-for-kte-c19?cid=CS-ZC-FT-189966
Sep 14, 2015 - The COMP has adopted a positive opinion regarding the granting of orphan drug status to Kite's (KITE) KTE-C19 for the treatment of PMBCL and MCL.
0
Stock Market News for September 11, 2015
http://www.zacks.com/stock/news/189724/stock-market-news-for-september-11-2015?cid=CS-ZC-FT-189724
Sep 11, 2015 - Benchmarks ended modestly higher on Thursday amid rise in oil prices and uncertainty about the timing of a rate hike
0
The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA
http://www.zacks.com/stock/news/189574/the-zacks-analyst-blog-highlights-amgen-tetraphase-geron-alexion-and-acadia?cid=CS-ZC-FT-189574
Sep 10, 2015 - The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA
0
Biotech Stock Roundup: Biosimilar Competition for Amgen, Tetraphase Hit By Disappointing Data
http://www.zacks.com/stock/news/189412/biotech-stock-roundup-biosimilar-competition-for-amgen-tetraphase-hit-by-disappointing-data?cid=CS-ZC-FT-189412
Sep 09, 2015 - What will be the impact of biosimilar competition on Amgen's (AMGN) Neupogen now that Zarxio has been launched in the U.S.?
0